Dublin, Dec. 14, 2017 (GLOBE NEWSWIRE) -- The "Flat-Rate Subscription to La Merie Publishing Reports & News Services" newsletter has been added to Research and Markets' offering.

Flat-Rate Subscription to La Merie Publishing Reports & News Services

A one-year subscription to this service provides access to:

• All existing La Merie Publishing reports on stock and listed online in the store;
• All new reports released by La Merie Publishing during the term of the subscription;
• 50 (weekly) issues of R&D Pipeline News

Among these reports are:

• Competitor Analysis reports in tabular presentation format;
• Brief Reports; and
• Full Reports.

Publishing activities include updates of existing reports as well as release of new reports.

Among La Merie Publishing News & Information Services are:

• R&D Pipeline News - Technology Edition;
• R&D Pipeline News - Therapeutic Area Edition.

After purchase of the Flat-Rate Subscription to La Merie Publishing Reports & News Services, credentials to access a dedicated server account with the report archive will be provided by e-mail. New issues of R&D Pipeline News and the R&D and Business Tracking Services will be delivered by e-mail, old issues are archived in the dedicated server account.

Coverage of reports:

La Merie Publishing has a special focus on biologics including, but not limited to:

• mRNA vaccines & therapeutics
• Oncolytic viruses
• Antibody-drug conjugates;
• Bispecific antibodies including T-cell or NK cell redirecting antibodies
• CAR & TCR engineered T-cells and NK cells;
• Immuno-oncology;
• Biosimilar antibodies and proteins
• Biosuperior antibodies;
• Therapeutic proteins;
• Therapeutic and prophylactic vaccines;
• Therapeutic peptides.

Reports of the Competitor Analysis Series deliver NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases and technologies provided in a tabular format and fully referenced.

Full Reports and Brief Reports provide in-depth description and analysis of targets, pipelines, companies and technologies.

Examples of Full Reports as of October 2017 are:

• mRNA Vaccines & Therapeutics 2017: an industry analysis of technologies, pipelines, stakeholders and deals
• The Oncolytic Virus Landscape 2017: an analysis of pipeline, stakeholders, deals, industry trends & opportunities
• TCR & CAR Engineered T-Cell and NK Cell Therapeutics 2016: Convergence of technologies opens business opportunities beyond CD19 CARTs
• T-Cell Redirecting Bispecific Antibodies 2016: A competitive landscape analysis of stakeholders, technologies, pipelines and deals

Examples of Brief Reports as of October 2017 are:

• CD22: a suitable antigen for targeted payload delivery by immunotherapeutics
• CD123: a paradigmatic target for immunotherapeutic treatment modalities
• B-Cell Maturation Antigen (BCMA): hot target for emerging treatment modalities

Examples of Competitor Analysis Reports as of October 2017 are:

• Mesothelin-Targeted Antibodies, Vaccines & T-Cells 2017
• Antibody-Drug Conjugate Pipeline Review by target, drug, phase and company
• Tumor Microenvironment Modulation via IDO, TGF-/R, CXCR4, CSF-1R, CD47-SIRPa, Adenosine, STING & Others
• Biosimilar and Biosuperior Therapeutic Antibodies
• PD-1 and PD-L1 Immune Checkpoint Inhibitors 2016
• Bispecific Antibodies for Cancer, Inflammatory & Other Diseases

Examples of Vaccine Reports

• Clostridium Difficile Vaccines and Therapeutics 2016
• Respiratory Syncytial Virus (RSV) Antibodies, Vaccines & Antivirals 2017

Examples of Peptide Reports

• Cancer Peptides
• Cardiometabolic Peptides
• Anti-Infective Peptides
• Cardiovascular Peptides
• Anti-Inflammatory Peptides

For more information about this newsletter visit https://www.researchandmarkets.com/research/pszsff/one_off_flatrate?w=12

CONTACT: Research and Markets
         Laura Wood, Senior Manager
         press@researchandmarkets.com
         For E.S.T Office Hours Call 1-917-300-0470
         For U.S./CAN Toll Free Call 1-800-526-8630
         For GMT Office Hours Call +353-1-416-8900
         Related Topics: Pharmaceuticals

Legal Disclaimer:

EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.